ArticlePlatelets2013
Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study.
Article in Platelets, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Systematic Review of miRNA as Biomarkers in Alzheimer's Disease.Molecular neurobiology · 2019Pooled it
- Platelet Dynamics in Neurodegenerative Disorders: Investigating the Role of Platelets in Neurological Pathology.Journal of clinical medicine · 2024Review
- Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging.International journal of molecular and cellular medicine · 2023Review
- Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimer's Disease? A Systematic Review.Life (Basel, Switzerland) · 2021Review
- β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.Alzheimer's research & therapy · 2020Review
- Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients.European archives of psychiatry and clinical neuroscience · 2019Article
- MicroRNA-135b has a neuroprotective role via targeting of β-site APP-cleaving enzyme 1.Experimental and therapeutic medicine · 2016Article
- A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype.Acta neuropathologica · 2014Article
- Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?Acta neuropathologica communications · 2014Review
- BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.Current Alzheimer research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
To date there is no validated peripheral biomarker to assist with the clinical diagnosis of Alzheimer's disease (AD). Platelet proteins have been studied as AD biomarkers with relative success. In this study, we investigated whether platelet BACE1 levels differ between AD and cognitively normal (CN) control patients. Using a newly developed ELISA method, we found that BACE1 levels were significantly lower in AD compared to CN subjects. These data were supported by the observation that several BACE1 isoforms, identified by Western blotting, were also lower in AD platelets. This proof-of-concept study provides evidence for testing platelet BACE1 levels as a peripheral AD biomarker using a novel, sensitive and inexpensive method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.